Podcasts about Harpoon

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

A Mix dedicated to that Friday Knock Off ⚡️Like the Show? Click the [Repost] ↻ button so more people can hear it!

Harpoon Fit FestA very unique and fun episode, joined by co-host Tim Ferraro.We sat down with: Conor Murphy of Big Night Fitness https://www.instagram.com/conortmurphy/https://www.instagram.com/bignightfitness/ Margarite Lee of MyStridehttps://www.instagram.com/margueriteleee/https://www.instagram.com/mystryde/ Stephen Ledogar of Big Night Fitness & CF Tilthttps://www.instagram.com/stephen.ledo/?hl=en https://www.instagram.com/bignightfitness/ https://www.instagram.com/crossfittilt/?hl=en Sal Martinez of Everybody Fightshttps://www.instagram.com/everybodyfights/ Casey Eagan of Ripple PThttps://www.instagram.com/casey.dpt/?hl=en https://www.instagram.com/ripple.boston/?hl=en Christina Muccio of The I Am Brand, Co-founder of Sanctuary Wellness Center and Instructor at BeSpokehttps://www.instagram.com/cmooch/ https://www.instagram.com/thisisiam.co/ https://www.instagram.com/sanctuarywellnesscenter/ @bspokestudiosLydia Flaherty of Club Sports Group / F45https://www.instagram.com/lydiaflaherty/ https://www.instagram.com/clubsportsgroup/ Christina Naftzger of F45 Bostonhttps://www.instagram.com/christina_naftzger/ Caleb & Miles of Common Dadhttps://www.instagram.com/common.dad/ Host: Tim Ferrarohttps://www.instagram.com/timferraro1/ Matt Sweeney of Strength and Sport PT https://www.instagram.com/mattsweeney.dpt/https://www.instagram.com/strengthandsport/ Now streaming on Youtube (video), Spotify (video) and Apple Podcasts. 

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

TRACKLIST: 01 - Tom Novy Feat Michael Marshall - Your Body (Andy Van Remix) 02 - Gadjo - So Many Times 03 - Deepswing - In The Music 04 - Armand Van Helden - I Want Your Soul 05 - Joey Negro - Make A Move On Me 06 - Michael Gray - The Weekend 07 - Armand Van Helden x Karen Harding - Wings (I Won't Let You Down) 08 - Luppi Clarke - Feel Me 09 - Harpoon, Jania - Heaven 10 - Technasia & Green Velvet - Suga (David Penn Remix) 11 - Luppi Clarke - Raw Affairs 12 - Martin Ikin feat. Hayley May - How I Feel #luppiclarke #djluppiclarke #HBFam #housemusic #house

Welcome to Issue 265 of Critical Encounters, a podcast about Marvel Champions, a Living Card Game by Fantasy Flight Games. Here we take a good look at that most critical piece of the game, the Encounter Sets. We'll discuss those poorly understood characters, unfairly labeled Villains, and their various plans to shape humanity and benefit the planet, as well as those so-called heroes intent on thwarting them. In this Secret Dossier we look at Harpoon's Nemesis Hero, Angel / Archangel You can find us on Discord as: Vardaen, bigfomlof, Maka, Lexicon Email us at: criticalencounterspod@gmail.com Follow us on Facebook at: https://www.facebook.com/criticalencounterspod/ Subscribe to our YouTube Channel: https://www.youtube.com/channel/UCg-r6-EooHoJGa1RRsH7i3w Find our Patreon: https://www.patreon.com/criticalencounterspodcast Find our Twitch: https://www.twitch.tv/vardaen You can also find our Discord Channel on the Marvel Champions Monthly Discord Server. Find Maka's Channel Here: https://www.youtube.com/@nightofthelivingcardgame Our Deck Lists: Daniel (Aggression) https://marvelcdb.com/deck/view/910176 Steve (Protection) https://marvelcdb.com/deck/view/907710?deck_name=Angel%20Protection%20-%20Critical%20Encounters Chris (Leadership) https://marvelcdb.com/deck/view/906300 Scott (Justice) https://marvelcdb.com/decklist/view/47911/justice-for-archangel-1.0   “Just relax and enjoy the flight" - Angel

John & Heidi share funny stories of people doing weird things... plus we continue our segment #AsSeenOnTV as John chats with Captain Joe Dion - Harpoon HuntersLearn more about our radio program, podcast & blog at www.JohnAndHeidiShow.com

Nadia Davari is an entertainment attorney with extensive experience across a spectrum of fields including film, television (both scripted and unscripted), documentaries, music, influencer branding, technology, fashion, and startups. She is known for her dynamic legal counsel and has also expanded her portfolio by executive producing and producing several notable projects. Some of her credits include "Senior Moment," "All There Is," "Harpoon," "Here's Yianni," "A Motel," "Workaholics," and "The Crusades."Ms. Davari's legal and production expertise is complemented by her active participation in educational and industry panels. She has shared her knowledge at prestigious institutions and events, including the USC School of Cinematic Arts, the USC School of Law's Entertainment Law Symposium, Southwestern Law School, UCLA School of Law, and Raindance LA Film School. She has also been a keynote speaker and panel moderator at renowned industry gatherings like Hollywood Women's Film Festival, Wonder Women Tech, Dances with Films, The Multi Cultural Film Festival, Bet Tzedek Legal Services, and the ScareLA horror convention.Ms. Davari earned her J.D. from the University of Southern California's School of Law. Her undergraduate education was completed at the University of California, Los Angeles, where she received a Bachelor of Science in Molecular, Developmental Biology, and Genetics—demonstrating her ability to bridge the worlds of science and entertainment with her diverse skill set.

Brandon Vogt with Captain Niko of the new show "Harpoon Hunters" on Discovery on News Radio KKOBSee omnystudio.com/listener for privacy information.

Each summer on Cape Cod, multi-generational fishing families race against the clock - and each other - to catch highly valuable Atlantic bluefin tuna using only 10-foot electrified spears. Time is of the essence as harpoon boats only have four weeks to catch as many fish as they can before the overall limit is met. With fish worth as much as $10K each, stakes are high for these expert fishermen to make ends meet for their families and beat the competition to take home these prize fish. Growing up a “dock rat” in Green Harbor, Joe Dion was obsessed with fishing. As soon as he was old enough, he took any job he could find: cutting rope off of propellers, painting boat bottoms, helping fish buyers. At 13, he started fishing on charter boats. By 25, he captained his own harpoon boat. With Mike Miller (aka “The Hacker”) as his driver, Joe became one of the most successful harpooners in the fishery. Sadly, in 2022, his 11-year-old son and 7-year-old daughter were diagnosed with a rare form of muscular dystrophy. Joe sold his boat and took two seasons off to raise awareness for the disease. Now, with his family in a better place, he's itching to get back on the water. With his old friend Mike by his side, Joe is ready to prove that lightning can strike twice. Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-like-it-s-live--4113802/support.

Each summer on Cape Cod, multi-generational fishing families race against the clock - and each other - to catch highly valuable Atlantic bluefin tuna using only 10-foot electrified spears. Time is of the essence as harpoon boats only have four weeks to catch as many fish as they can before the overall limit is met. With fish worth as much as $10K each, stakes are high for these expert fishermen to make ends meet for their families and beat the competition to take home these prize fish. Growing up a “dock rat” in Green Harbor, Joe Dion was obsessed with fishing. As soon as he was old enough, he took any job he could find: cutting rope off of propellers, painting boat bottoms, helping fish buyers. At 13, he started fishing on charter boats. By 25, he captained his own harpoon boat. With Mike Miller (aka “The Hacker”) as his driver, Joe became one of the most successful harpooners in the fishery. Sadly, in 2022, his 11-year-old son and 7-year-old daughter were diagnosed with a rare form of muscular dystrophy. Joe sold his boat and took two seasons off to raise awareness for the disease. Now, with his family in a better place, he's itching to get back on the water. With his old friend Mike by his side, Joe is ready to prove that lightning can strike twice. Niko spent his childhood fishing with his dad, Bill, a legendary harpooner and advocate for harpooners' rights. It's no surprise that he ended up harpooning by his dad's side as an adult. Sadly, Bill passed away in 2022. Now Niko is determined to carry on his father's legacy, but with the Ezyduzit's track record of landing 50 Bluefin per season, he has a lot to live up to. Luckily, Niko is a fearsome competitor. Since age 14, he has taken part in Strong Man competitions. At 29, he won the IPL World Powerlifting Championship. This will be his first year captaining the Ezyduzit, and Niko is driven to score big for his dad.Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

It's 2025 and we're starting the year off with a bang. Regular fans will know that we always start the year off with a big artist, and there's very few metal bands bigger than Black Sabbath. This week and next we'll be chatting all about them. Episode one is an in-depth interview with Aron Ward, son of Black Sabbath's original drummer, Bill Ward. Aron discusses his eclectic musical journey, influenced heavily by his father but also carved by his own diverse tastes. He talks about his own projects, such as Olanza, Harpoon, and Repoman, and his approach to DIY music production. Aron provides personal anecdotes from his childhood, touring with Black Sabbath, and learning the harsh realities of the music industry. He also shares his thoughts on various Sabbath albums and his dad's impact on his music career. Tune in for a fascinating chat filled with music history, personal stories, and candid insights. NEXT WEEK we're bringing in ANOTHER guest to talk about the band, and focus on the record Never Say Die. 00:00 Welcome and Introduction 00:08 Meet Aron Ward 01:46 Aron's Musical Journey 03:22 Growing Up with Black Sabbath 04:35 Influence of Black Sabbath 16:13 DIY Ethos and Industry Insights 20:13 Memories and Reflections 23:56 Favorite Albums and Musical Preferences 26:33 Interviewing Ian McKay: A Shared Experience 26:54 Heaven and Hell: A New Kind of Metal 27:29 Living in Bel Air: Ozzy's Absence 29:50 The Dio Era: A Divisive Time 32:25 Technical Ecstasy: A Beatles Influence 33:56 Never Say Die: A Confusing Time 39:07 The Influence of Sabbath on Modern Bands 45:03 Final Thoughts and Personal Projects

Welcome back to the Proper True Yarn Podcast, where the yarns are wild, the laughs are loud, and the stories are proper true—maybe with just a bit of extra seasoning. This episode features none other than the legendary Jeff Perot, who's got a treasure trove of outrageous tales straight from the Aussie outback.First, Jeff takes us back to a snake-killing adventure that nearly ends in disaster, with a shot that blows a garden rake sky-high and sends the whole crew into a panic. And then there's the time Jeff ended up in a hospital with an infection, but ended up dodging a "harpoon needle" and making a daring escape in full cowboy regalia, only to get caught by the cops.We also get a wild yarn about legless lizards and metho, with a hilarious twist involving Jeff's mate "Gnarly Ryan." Not to mention a kitchen disaster starring Mrs. Mahoney, a cook whose culinary skills were... let's just say, unforgettable.This episode is a proper cracker, packed with all the classic Aussie humor, outback mischief, and Jeff's legendary storytelling. You won't want to miss it!#propertrueyarn Hosted on Acast. See acast.com/privacy for more information.

Leaders of the newly former Barrel One Collective shared their vision for the new platform, which was formed from the merger of Harpoon Brewery's parent company Mass. Bay Brewing and Smuttynose's home of FinestKind Brewing.    Harpoon co-founder and CEO Dan Kenary and FinestKind CEO Steve Kierstead explained how the platform came together, how open they are to adding to the collective and the types of partners they'd welcome, and how they're approaching innovation with a portfolio that now boasts 14 brands.    Kenary also discussed the circumstances that led to the end of Harpoon's employee stock ownership plan (ESOP). Moving forward, Kenary will lead Barrel One as CEO, while Kierstead will move into the role of chief commercial officer.    Plus, Brewbound editor Justin Kendall and managing editor Jess Infante share their history covering Mass. Bay and Smuttynose and dive into the latest headlines, including the surgeon general's advisory calling for cancer warnings on bev-alc labels and WWE's investment in Hulk Hogan's Real American Beer.

This week the guys get into the Christmas spirit. We exchange gifts, someone has a couple too many drinks at Harpoon, and we discuss some recent office holiday party experiences. Whole 9 Hotline: 978-315-0332 Twitter/Instagram/TikTok: @TW9Ypod Pesto's Instagram: ayo_its_pesto Jenna's Cookie Instagram: jsprinks_Cookies

In our final episode of 2024, we celebrate Christmas. We touch on fruit cake and figgy pudding (Thoughts?). Vacation v2.0 took us to Hocking Hills, Ohio for some amazing hiking. Have you ever seen liqueur prices in Ohio? We talk about why pricing is the way it is there. We took an evening run to Rochester to enjoy dinner at JoJo's and to pick up our advent box from K2 Brewing. Jason and Bri list their top 3 Christmas movies. We talk about our return to the Deck The Halls event on Seneca Lake. Featuring holiday brews from Shiner, Harpoon, Southern Tier, and War Horse Brewing.Send us a text at the Buffalo Brews Podcast and let us know what you think of the episode.Visit our website at BuffaloBrewsPodcast.comEmail: buffalobrewsPR@gmail.comFollow us on social media.Instagram: @BuffaloBrewsPodcast Facebook: @BuffaloBrewsPodcastX/Twitter: @BuffaloBrewsPod

Links1. “Operational Tripolitan,” by Jared Samuelson, CIMSEC, December 13, 2019. 2. Volunteer for CIMSEC.3. Write for CIMSEC. Mentioned Podcasts (in order): 4. Sea Control 380: Underwriters of the United States with Dr. Hannah Farber.5. Sea Control 460: Hulks of the Hamoaze with Emma Haddon.6. Sea Control 269: General David Berger, Commandant of the United States Marine Corps.7. Sea Control 219: Admiral Karl Schultz, Commandant of the United States Coast Guard.8. Sea Control 169: Larry Bond and Sebastian Bruns on Harpoon, Red Storm Rising and Tom Clancy.9. Sea Control 440: The Wager with David Grann.10. Sea Control 20: Byan McGrath on Maritime Strategy.11. Sea Control 260: The Best Defense is a Good Offense with ENS Kara Dowling.12. Sea Control 203: A Near Miss with LTJG (ret.) Ken Sanger.13. Sea Control 256: Reporting From the Sea with Ian Urbina.

By Jared Samuelson Larry Bond, the creator of the naval wargame Harpoon and coauthor of Red Storm Rising, joins the program. Larry discusses how he got into wargaming and his experience running wargames in the U.S. Navy. Download Sea Control 556 – Wargaming with Larry Bond Links 1. Sea Control 169 – Larry Bond and … Continue reading Sea Control 556 – Wargaming with Larry Bond →

LinksSea Control 169 – Larry Bond and Sebastian Bruns on Harpoon, Red Storm Rising, and Tom Clancy

NasCardRadio Episode 209: The guys review last week's Watkins Glen International Xfinity Series (Connor Zilisch) and Cup (Chris Buescher) race winners, highest finishing rookies (Shane Van Gisbergen and Carson Hocevar) and their rookie trading cards. Over at the Azerbaijan Grand Prix Oscar Piastri had a commanding win and the guys review his first trading cards. At IndyCar's final 2024 race, Colton Herta got the Big Machine Music City Grand Prix win and the guys review his first trading cards. Next the guys check out the print run for 2024 Panini Instant NASCAR card #1. These print runs are not recorded on the Panini web site and are only available on a physical card. In the main segment Logan set off on a quest to land two of his NasCard white whales and pulls it off on the same day. You will not want to miss the recap of his trip to the Charlotte area last week. Finally, the guys end the show with some groovy eBay racing card auctions in ‘The Kings Court'. #thehobby #tradingcards #panini 

Wicked, Travis, Fae, and Dread celebrate Friday the 13th:  The Final Chapter or is it?!  Travis Blames Eli Roth. Who Do You Want To Be Today?  Bear Puns. More Influencer Horror. Sexaful. Timeline Man. Getting My Tims Wrong. Devils Eggs. Lad L. Hunger Demons. Narrating His Own Death. Dead Fook. Hateable Not Hateful. He Killed a Tent. Harpoon to the Junk. The Chick in the Boat. Dead Fook. I Would Have Liked to See Her Die. Axe Ballistics. Smell Gives Jason Away. Juicy Jason. Help our friends at Achewillow get their book published: https://www.inkshares.com/books/achewillow-book-1 Support us on Patreon at patreon.com/GORE13 Check out our website created by Baumbie GOREpodcast.com Follow the show on Twitter @GOREpodcast  Email the show at GOREpodcast13@gmail.com

Holly Isnor is the Marine Campaign Coordinator with the Ecology Action Centre in Nova Scotia, and our  guest on The Blue fish Radio Show. Holly will explain why the 184 fishers in Nova Scotia that hold swordfish harpoon licenses are interested in adding the option of filling their quota using hook-and-line, and bringing along paying customers interested in reeling in swordfish that can reach weights of 500 kilograms. Find out what it's going to take to open up this new big game recreational fishing opportunity.

Dr. Allison Zibelli and Dr. Erika Hamilton discuss the results of the DESTINY-Breast06 trial in HR+, HER2-low and HER2-ultralow metastatic breast cancer and the A-BRAVE trial in early triple-negative breast cancer, the results of which were both presented at the 2024 ASCO Annual Meeting. TRANSCRIPT Dr. Allison Zibelli: Hello, I'm Dr. Allison Zibelli, your guest host of the ASCO Daily News Podcast. I'm an associate professor of medicine and breast medical oncologist at the Sidney Kimmel Cancer Center of Jefferson Health in Philadelphia. My guest today is Dr. Erika Hamilton, a medical oncologist and director of breast cancer research at the Sarah Cannon Research Institute. We'll be discussing the DESTINY-Breast06 trial, which showed a progression-free advantage with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) compared to chemotherapy in hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer. We'll address the implications of this study for the community, including the importance of expanding pathology assessments to include all established subgroups with HER2 expression, and the promise of expanding eligibility for antibody-drug conjugates. We'll also highlight advances in triple-negative breast cancer, focusing on the A-BRAVE trial, the first study reporting data on an immune checkpoint inhibitor avelumab in patients with triple-negative breast cancer with invasive residual disease after neoadjuvant chemotherapy.  Our full disclosures are available in the transcript of this episode.  Erika, it's great to have you on the podcast today. Dr. Erika Hamilton: Thanks so much, Allison. Happy to join. Dr. Allison Zibelli: Antibody-drug conjugates are rapidly changing the treatment landscape in breast cancer. The data from the DESTINY-Breast06 trial suggests that trastuzumab deruxtecan may become a preferred first-line treatment option for most patients with HER2-low or HER2-ultralow metastatic breast cancer after progression on endocrine therapy. First, could you remind our listeners, what's the definition of HER2-ultralow and what were the findings of this trial? Dr. Erika Hamilton: Yeah, those are fantastic questions. Ultralow really has never been talked about before. Ultralow is part of a subset of the IHC zeros. So it's those patients that have HER2-tumor staining that's less than 10% and incomplete but isn't absolutely zero. It's even below that +1 or +2 IHC that we have classified as HER2-low. Now, I think what's important to remember about D-B06, if you recall, D-B04 (DESTINY-Breast04) was our trial looking at HER2-low, is that D-B06 now included HER2-low as well as this HER2-ultralow category that you asked about. And it also moved trastuzumab deruxtecan up into the frontline. If you recall, D-B04 was after 1 line of cytotoxic therapy. So now this is really after exhausting endocrine therapy before patients have received other chemotherapy. And what we saw was an improvement in progression-free survival that was pretty significant: 13.2 months versus 8.1 months, it was a hazard ratio of 0.62. And you can ask yourself, “well, was it mainly those HER2-low patients that kind of drove that benefit? What about the ultralow category?” And when we look at ultralow, it was no different: 13.2 months versus 8.3 months, hazard ratio, again, highly significant. So I think it's really encouraging data and gives us some information about using this drug earlier for our patients with hormone receptor-positive but HER2-negative disease.  Dr. Allison Zibelli: I thought this study was really interesting because it's a patient population that I find very difficult to treat, the hormone receptor-positive metastatic patient that's not responding to endocrine therapy anymore. But it's important to mention that T-DXd resulted in more serious toxicities compared to traditional chemotherapy in this study. So how do you choose which patients to offer this to? Dr. Erika Hamilton: Yeah, those are both great points. So you're right, this is after endocrine therapy. And in fact, about 85% of these patients had received at least 2 prior lines of endocrine therapy. So I have some people kind of asking, “Well, if endocrine therapy really isn't benefiting everyone in the second-line setting post-CDK, should we just move to the ADCs?” And, no, probably we should really make sure that we're exhausting endocrine therapies for those patients that are going to benefit. And once we determine somebody has endocrine-resistant disease, that's when we would think about switching. In terms of the side effects, I think you're right. It's mainly ILD that's probably the more serious side effect that we worry about a little bit with trastuzumab deruxtecan. The good news is, through multiple trials, we've gotten a little bit better at managing this. We've pretty much all but eliminated any fatal cases of ILD, definitely less than 1% now. ILD rates, depending on what study you look for, kind of ranges in that 10% to 15% range. Any grade ILD on D-B06 was 11.3%. So really kind of making sure that we look for ILD at scans, making sure that patients are educated to tell us about any new pulmonary symptoms: cough, exertional dyspnea, shortness of breath at rest, etc. But I think the most common side effects that we really deal with on a daily basis with trastuzumab deruxtecan, luckily, is nausea, which we've gotten better at managing with the 2- or 3-drug antiemetic regimen, and probably a little bit of fatigue as well. Dr. Allison Zibelli: Thank you. So, I think for most people in the community, the sticking point here will be expanding pathology assessments to include all of the subgroups, including the ultralow. Most patients in the community are not testing for HER2-low and HER2-ultralow now. Dr. Erika Hamilton: Historically, we kind of all did HER2 IHC, right? And then as FISH became available, there were a lot of institutions that moved to FISH and maybe didn't have IHC anymore. And now, at least in my institution, we do both. But I think it's a very important point that you made that IHC was really designed to pick out those patients that have HER2-high, the 3 pluses or the FISH amplified cases. It was not to tell the difference between a 1+ or a 2+ or a 0 that's not quite a 0 and a 1+. So I think you're right. I think this is tough. I probably have a little bit more of an interesting take on this than some people will. But data from ASCO, not this year but in 2023, there was actually a pretty eloquent study presented where they looked at serial biopsies in patients, and essentially, if you got up to 4 or 5 biopsies, you were guaranteed to have a HER2-low result. Now, this didn't even include ultralow, which is even easier. If we know we include ultralow, we're really talking about probably 85% to 90% of our patients now that have some HER2 expression. But if we biopsy enough, we're guaranteed to get a HER2 low.  And so I think the question really is, if we know IHC wasn't really designed to pick out these ultralows, and we know kind of greater than 90% of patients are going to have some expression, did we kind of develop this drug a little bit backwards? Because we thought we understood HER2, and the reality is this drug is a little bit more like a sacituzumab govitecan, where we don't test for the TROP2. Should we really be kind of serial biopsying these patients or should maybe most patients have access to at least trying this drug?  Dr. Allison Zibelli: So I don't think that most of my patients will really be happy to sign up for serial biopsies. Dr. Erika Hamilton: Agreed. Dr. Allison Zibelli: Do we have any emerging technologies for detecting low levels of HER2? You talked about how the IHC test isn't really designed to detect low levels of HER2. Do you think newer detection techniques such as immunofluorescence will make a difference, or will we have liquid biopsy testing for this? Dr. Erika Hamilton: Yeah, I think liquid biopsy may be a little bit hard, just because some of those circulating tumor cells are more of a mesenchymal-type phenotype and don't necessarily express all of the same receptors. Normally, if they're cytokeratin-positive, they do, but certainly there is a lot out there looking at more sensitive measures. You mentioned immunofluorescence, there are some even more quantitative measures looking at lower levels of HER2. I definitely think there will be. I guess, ultimately, with even the IHC zeros that are the less than 10% incomplete staining, having a PFS that was absolutely no different than the HER2 low, I guess the question is, how low can we really go? We know that even the IHC zeros doesn't mean that there's no HER2 expression on the cell surface. It just means that maybe there's a couple of thousand as opposed to 10,000 or 100,000 copies of HER2. And so it really appears that perhaps this drug really is wedded to having a lot of HER2 expression. So ultimately, I wonder how much we're going to have to use those tests, especially with what we know about tumor heterogeneity. We know that if we biopsy 1 lesion in the liver, biopsy a lymph node, or even another lesion in the liver, that the HER2 results can have some heterogeneity. And so ultimately, my guess is that most people have some HER2 expression on their breast cancer cells. Dr. Allison Zibelli: So maybe we're going to be using this for everybody in the future. Dr. Erika Hamilton: It certainly seems like we keep peeling back the onion and including more and more patients into the category that are eligible to receive this. I agree. Dr. Allison Zibelli: Let's move on to triple-negative breast cancer, namely the A-BRAVE trial. This was an interesting trial for patients that did not get neoadjuvant immunotherapy and testing 2 groups. The first group was those with residual disease after neoadjuvant conventional chemotherapy. The second group was people with high-risk disease identified upfront that had upfront surgery. The study found that adjuvant avelumab did not improve disease-free survival versus observation, which was the study's primary endpoint. But interestingly, there was a significant improvement in 3-year overall survival and distant disease-free survival. Can you give us your thoughts on that? Dr. Erika Hamilton: Yeah, I think this study was really interesting. Right now, the standard for our patients with larger or node-positive triple-negative cancers is KEYNOTE-522. It's a pretty tough regimen. It's kind of 2 sequential uses of 2 chemotherapies, so 4 chemotherapy agents total with pembrolizumab. But you're right, this study looked at those that had residual disease after neoadjuvant that didn't include immunotherapy, or those patients that didn't get neoadjuvant therapy, went to surgery, and then were receiving chemotherapy on the back end. I'm going to give you the numbers, because you're right. The 3-year disease-free survival rates were not statistically significant. It was 68.3% among those that had avelumab, 63.2% with those that had observation only. So the difference was 5.1% in favor of avelumab, but it wasn't statistically significant. A p value of 0.1, essentially. But when we looked at the 3-year overall survival rates, we saw the same pattern, those patients with the avelumab doing better, but it was 84.8% overall survival and not, unfortunately, dying, versus 76.3%. So the magnitude of benefit there was 8.5%, so about 3% higher than we saw for disease-free survival, and this was statistically significant.  So is this going to change practice for most patients? I probably don't think so. I think for our patients that have larger tumors that's recognized upfront or have node positivity, we're probably going to want to use neoadjuvant chemo. Being able to get a PCR is very prognostic for our patients and enables us to offer things on the back end, such as PARP inhibitors or further chemotherapy of a different type of chemotherapy. But for our patients that go to surgery and maybe the extent of their disease just isn't recognized initially, this could be an option. Dr. Allison Zibelli: I agree. I think this will be a really useful regimen for patients where we get the surprise lymph node that we weren't expecting, or somebody who comes to us, maybe without seeing the medical oncologist, who got upfront surgery. So I thought this was really interesting. What kind of translational studies do you think we're going to do to try and understand which patients would benefit from avelumab? Dr. Erika Hamilton: Yeah, I think that's a great question, and honestly, it's a question that we haven't really answered in the neoadjuvant setting either. Immunotherapy in breast cancer is just a little bit different than it is in some other diseases. We have a benefit for those patients that are PD-L1 positive in the first line. We really haven't seen benefit for metastatic outside of first line. And then in neoadjuvant, it was among all comers. We don't have to test for PD-L1. And now we have this avelumab data from A-BRAVE. I think the question is, is there's probably a subset of patients that are really getting benefit and a subset that aren't. And I don't know that PD-L1 testing is the right test. We know a lot of people are looking at TILs, so kind of lymphocytes that are infiltrating the tumor, a variety of other kind of immunologic markers. But my guess is that eventually we're going to get smart enough to tease out who actually needs the immunotherapy versus who isn't going to benefit. But we're not quite there yet. Dr. Allison Zibelli: Thank you, Erika, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Erika Hamilton: Thanks so much for having me.  Dr. Allison Zibelli: And thank you to our listeners for joining us. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you value our insights, please take a moment to rate, review, and subscribe wherever you get your podcasts. It really helps other people to find us. So thank you very much for listening today.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Find out more about today's speakers:  Dr. Allison Zibelli Dr. Erika Hamilton @ErikaHamilton9   Follow ASCO on social media:  @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures: Dr. Allison Zibelli:  None Disclosed   Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Welcome to Issue 230 of Marauder Champions Monthly, a podcast about Marvel Champions, a Living Card Game by Fantasy Flight Games. Here we take a good look at that most critical piece of the game, the Marauders. We'll discuss those poorly understood characters, unfairly labeled Villains, and their various plans to shape mutant kind and benefit the planet, as well as those so-called heroes intent on thwarting them. In this MCM Shadow of the Past Issue we take a look at Angel's Nemesis, Harpoon. You can find us on Discord as: Vardaen, bigfomlof, WanderingTook, and Maka Email us at: criticalencounterspod@gmail.com Follow us on Facebook at: https://www.facebook.com/criticalencounterspod/ Subscribe to our YouTube Channel: https://www.youtube.com/channel/UCg-r6-EooHoJGa1RRsH7i3w Find our Patreon: https://www.patreon.com/criticalencounterspodcast Find our Twitch: https://www.twitch.tv/vardaen You can also find our Discord Channel on the Marvel Champions Monthly Discord Server.  “Foolish children… save yourselves… from the energy weapon… of Harpoon!” -- Harpoon  

This week The Lonely Island and Seth talk about the digital short Harpoon Man, plus they cover a ton of sketches from three different SNL episodes! Harpoon Man - https://www.youtube.com/watch?v=pJodKiA2LJgBlizzard Man - https://www.youtube.com/watch?v=l2r3dBNDRugNational Anthem - https://www.youtube.com/watch?v=VUT80JVy3v4Bossa Nova - https://www.youtube.com/watch?v=qzf57tzXrO4(Not all the clips we mention are available online; some never even aired.)If you want to see more photos and clips follow us on Instagram @thelonelyislandpod. Vuori is offering 20% off your FIRST purchase. Get yourself some of the most comfortable and versatile clothing on the planet at vuori.com/ISLAND. Not only will you receive 20% off your first purchase, but enjoy free shipping on any U.S. orders over $75 and free returns.    Produced by Rabbit Grin ProductionsExecutive Producers Jeph Porter and Rob HolyszLead Producer Kevin MillerCreative Producer Samantha SkeltonCoordinating Producer Derek JohnsonCover Art by Olney AtwellMusic by Greg Chun and Brent AsburyEdit by Cheyenne JonesMix and Master by Jason Richards

Thu, 27 Jun 2024 23:00:00 GMT http://relay.fm/downstream/72 http://relay.fm/downstream/72 Jason Snell TV critic Tim Goodman guests to discuss the WBD and Paramount messes and give an update about what he's been up to over at his Substack. [Downstream+ subscribers get to hear us talk about a very weird New York Times article about media moduls on a yacht.] TV critic Tim Goodman guests to discuss the WBD and Paramount messes and give an update about what he's been up to over at his Substack. [Downstream+ subscribers get to hear us talk about a very weird New York Times article about media moduls on a yacht.] clean 2479 TV critic Tim Goodman guests to discuss the WBD and Paramount messes and give an update about what he's been up to over at his Substack. [Downstream+ subscribers get to hear us talk about a very weird New York Times article about media moduls on a yacht.] Guest Starring: Tim Goodman Links and Show Notes: Get Downstream+ and don't miss a segment! Submit Feedback CNN Reportedly Exploring Digital Subscriptions as News Gets the Streaming Treatment | PYMNTS.com 'Harry Potter' HBO Series Hires Writer, Director Dish Bundles Netflix for Free With New Two-Year Offer Paramount Chiefs: We're Cutting $500 Million in Costs After Profit Drop Shari Redstone's Paramount Sale Options: Who's In the Mix Now? Kanopy - Stream Classic Cinema, Indie Film and Top Documentaries hoopla | streaming audiobooks, music, video & ebooks Hoopla,

Thu, 27 Jun 2024 23:00:00 GMT http://relay.fm/downstream/72 http://relay.fm/downstream/72 Harpoon Gun Salvaged from the Wreckage 72 Jason Snell TV critic Tim Goodman guests to discuss the WBD and Paramount messes and give an update about what he's been up to over at his Substack. [Downstream+ subscribers get to hear us talk about a very weird New York Times article about media moguls on a yacht.] TV critic Tim Goodman guests to discuss the WBD and Paramount messes and give an update about what he's been up to over at his Substack. [Downstream+ subscribers get to hear us talk about a very weird New York Times article about media moguls on a yacht.] clean 2479 TV critic Tim Goodman guests to discuss the WBD and Paramount messes and give an update about what he's been up to over at his Substack. [Downstream+ subscribers get to hear us talk about a very weird New York Times article about media moguls on a yacht.] Guest Starring: Tim Goodman Links and Show Notes: Get Downstream+ and don't miss a segment! Submit Feedback CNN Reportedly Exploring Digital Subscriptions as News Gets the Streaming Treatment | PYMNTS.com 'Harry Potter' HBO Series Hires Writer, Director Dish Bundles Netflix for Free With New Two-Year Offer Paramount Chiefs: We're Cutting $500 Million in Costs After Profit Drop Shari Redstone's Paramount Sale Options: Who's In the Mix Now? Kanopy - Stream Classic Cinema, Indie Film and Top Documentaries hoopla | streaming audiobooks, music, video & ebooks Hoopla, Kanopy and

BEFORE FURIOSA: A MAD MAX SAGA!! Mad Max Fury Road Full Movie Reaction Watch Along:  https://www.patreon.com/thereelrejects LIQUID IV: Visit http://www.liquidiv.com & use Promo Code: REJECTS  Mad Max Fury Road Reaction, Recap, Commentary, Analysis, Spoiler Review, Breakdown, & Ending Explained - not exactly my first time watching but in my eyes it is cause I wasn't able to pay attention due to...poor decisions in life. BUT NOW, I can finally take this movie in and fortunately, I don't remember a dang thing, so I can witness the glory - WITNESS ME witness Fury Road before Furiosa Review with Anya Taylor Joy & Chris Hemsworth, we journey with Tom Hardy (Venom & The Dark Knight Rises) taking over the Mel Gibson role, Charlize Theron as Furiosa, Immortan Joe, Nicholas Hoult as Nix, Zoe Kravitz and more to round out the cast as we go through INSANE action scenes such as The Chase Begins, Max vs Furiosa Scene, Bikers Attack The Rig, Desert Battle, Furiosa Gets Her Revenge, Attack On The War Rig, Harpoon and The pole, Stuck in the mud blue, "I Live, I Die, I Live Again", "What A Lovely Day" & MORE from director George Miller, the man behind The Road Warrior.  Support The Channel By Getting Some REEL REJECTS Apparel! https://www.rejectnationshop.com/ Music Used In Manscaped Ad:  Hat the Jazz by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ POWERED BY @GFUEL Visit https://gfuel.ly/3wD5Ygo and use code REJECTNATION for 20% off select tubs!! Head Editor: https://www.instagram.com/praperhq/?hl=en Co-Editor: Greg Alba Co-Editor: John Humphrey Music In Video: Airport Lounge - Disco Ultralounge by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Ask Us A QUESTION On CAMEO: https://www.cameo.com/thereelrejects Follow TheReelRejects On FACEBOOK, TWITTER, & INSTAGRAM:  FB:  https://www.facebook.com/TheReelRejects/ INSTAGRAM:  https://www.instagram.com/reelrejects/ TWITTER:  https://twitter.com/thereelrejects Follow GREG ON INSTAGRAM & TWITTER: INSTAGRAM:  https://www.instagram.com/thegregalba/ TWITTER:  https://twitter.com/thegregalba Learn more about your ad choices. Visit megaphone.fm/adchoices

And the winner is… America, obviously.  The Beering Ain't Easy podcast embarks on a blind tasting adventure through the most recognizable American Lager macro beers and one notable exception - Troy Aikman's patented Eight Beer.  Can Troy's beer redeem the Cowboys playoff losing streak, or will he be relegated to the Keystone Light division?   Will Ryan's love of conspiracy theories finally pay off in a big way by being the first to uncover Houston Brewery moves?  And lastly, will Ryan love or hate his Nickelback concert experience?  You don't want to miss this one.Featured Beers:Bud Light.  Anheuser Busch, St Louis, MO. 4.2% ABVMiller Lite. Miller Brewing Company, Milwaukee, WI. 4.2% ABVCoors Light. Coors Brewing Company, Golden, CO. 4.2% ABVPabst Blue Ribbon.  Pabst Brewing Company, San Antonio, TX. 4.8% ABVEight Elite Light Lager. EIGHT Brewing Co, ?? United States.  4% ABV Other Shout-Outs:Troy Airman / Dallas CowboysBarry Switzer / University of OklahomaFaubourg Brewing Co.  New Orleans, LAVerona, WIOregon State Food Science DeptPhil Leinart (AB, Harpoon, Ommegang)Gayle Benson:  New Orleans Saints, PelicansKeystone LightMichelob UltraHipster Sauce11 Below BrewingFortress BrewingB-52 BrewingX FilesSalt & Oak Brewing / HazeboizNickelback / Houston Rodeo / Houston ChronicleDrake/Bun-BVector Brewing, Dallas, TXOak Highlands Brewing, Dallas, TX HTOWN Brewery Challenge Tracker - See how we're doing on our challenge to visit all breweries within 50 miles of Houston!WEBSITE and MERCH PAGE!  Check out all the great podcasts that are a part of Cross the Streams media!https://www.crossthestreamsmedia.com/show/beering-aint-easy/ Follow @beeringainteasy on Facebook, Instagram, X,Threads, or YouTube, email us at beeringainteasy@gmail.com, or follow our beer quest on Untappd, username BeeringAintEasyDrew.

Listen & subscribe on Apple, Google, Spotify, and other platforms. Welcome everyone to the weekly San Diego Tech News by Neal Bloom and Fred Grier from Fresh Brewed Tech. I'm Neal Bloom from Fresh Brewed Tech, the Tacos and Tech Podcast, and Interlock Capital. I'm Fred Grier, journalist and author of The Business of San Diego substack. I wrote about the tech industry for the San Diego Business Journal for two years. I covered the ins-and-outs of the startup world for much of that time, breaking news on IPOs, fundraising rounds, and M&A. Promote the show:  Before we dive in, we wanted to ask our listeners and SD Tech fans to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup Community.   4/8 Biolinq raise Natilus - Interlock participating in their latest round Defense tech ecosystem Harpoon defense tech meetup debrief Alterome Therapeutics raises $132M Series B Splash raise $4.5m Tide Rock acquires CABLENET Aerospace   Events - For full list - check The Social Coyote SaaS Diego – Fundraising for your SaaS Startup April 9 Welcome to SD Virtual Gathering - April 19 TechCon SoCal May 24 Founders Hike May 10

In today's episode of the Captain Paul Watson Foundation Podcast we get the chance to hear the courageous story of Elissa Phillips.  In September of 2023, Elissa and Anahita Babaei delayed the departure of Kristján Loftsson's harpoon ships by climbing into the crow's nests.   Elissa shares with us what the whole experience was like, and even gives us a glimpse into her experiences as a volunteer for the CPWF UK monitoring the whaling station in Iceland.  The courage of Elissa and Anahita is sure to inspire you.If you would like to learn more about the opportunity to win VIP tickets to a Red Hot Chili Peppers concert - please click here - http://donorbox.org/red-hot-chili-peppersThe winner will be announced on May 1, 2024Anthony Kiedis has been a long time supporter of Captain Paul Watson, and we are very appreciative of him donating this amazing experience for one of our supporters.Support the showhttps://www.paulwatsonfoundation.org/https://shop.paulwatson.com/

Grab your D20 and join us in Toffy Town for an adventurous new episode of LIVE! Special guest Dan Haskins takes up temporary residency in the Bungalow and leads the Boiz on a quest full of mystery and danger. Matt gets pushed into a koi pond. Nate wakes up in the Butterfingers' bedroom. Pat rips a child's head in half with his bare hands. Plus, what dark power is taking over this town? Why have the Boiz been brought here? Do the answers lie in the bar down the street? Takes one to cleave one and it all happens LIVE!

The legend goes on.....

Join our Entre CommunityInstagramTwitter YouTubeTikTokLinkedInAnd now for this week's prescription:On this week's dose, we have Larsen Jensen, former Olympic swimmer, Navy Seal, and current founder and General Partner at Harpoon Ventures. Larsen has always surrounded himself with some of the highest performers and most successful people, whether in the water next to the likes of Michael Phelps and Ryan Lochte, or out in the battlefield serving our country.It was only after a friend mentioned vc as a potentially exciting career path that Larsen realized he could leverage his experiences, especially regarding the government's growing partnership with the private sector in investing in new technology. In the interview, you will hear more about how he started Harpoon Ventures, some notable portfolio companies, as well as his outlook on the next few years in venture capital.We close out this week's dose with a short discussion on the future of AI, some awesome advice to the Pillgrims, and some great perspective from Larsen reflecting on his experience getting an MBA at Stanford. It was a pleasure hosting Larsen on this week's dose, and we're excited to share our conversation with you all. Sources:https://harpoon.vc/https://www.linkedin.com/in/larsen-jensen/Music Credit: Chapter One by Cole Bauer and Dean Keetonhttps://www.colebauer.com/https://www.instagram.com/deankeeton/?hl=enDisclosure:The views, statements, and opinions,  expressed herein by the hosts and guests are their own, and their appearance on the podcast should not be construed as reflecting the views or implied endorsement of Independent Brokerage Solutions LLC or any of its officers, employees, or agents. The statements made herein should not be considered an investment opinion, advice, or a recommendation regarding securities of any company. This podcast is produced solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy a security.

Team member Ryder Devoe talks with host Kieran Anderson about his passion for harpooning swordfish in Encinitas, California, and introduces us to the basic principles of the sport. Topics discussed in this episode with Ryder Devoe:·       Ryder's background and how he got into harpooning·       Harpooning overview and setup process·       Ryder's biggest swordfish catch·       A glimpse into a day of harpooning·       Harpoon components and techniques·       Major challenges targeting swordfish·       Ryder's harpooning tips and tricks·       Favorite harpooning memory ·       Other upcoming tripsFollow Kieran Anderson on Instagram at https://www.instagram.com/kieranand3rson/Follow Ryder Devoe's Instagram at https://www.instagram.com/ryderdevoe/Follow Salt Life on Instagram at https://www.instagram.com/realsaltlife/Shop Salt Life apparel at www.saltlife.com

Timo Time! The New Jersey Devils harpoon the San Jose Sharks 7-2.By Sam Woo and Scottyhttp://JoinOurCrew.comhttps://pucksandpitchforks.comhttps://www.LetsGoDevils.comRATE, REVIEW, AND SUBSCRIBE: Apple Podcasts - https://podcasts.apple.com/us/podcast/lets-go-devils-podcast/id1371371669 #NJDevils #NHL #LetsGoDevils #LGD #Devils #NewJersey #NCAA #AHLBecome a supporter of this podcast: https://www.spreaker.com/podcast/let-s-go-devils-podcast--2862943/support.

GEN AI summary! #LetsGoLarsen Jensen, a former Olympic swimmer turned investment guru, has an impressive background that spans from the swimming pool to the Navy SEAL teams, and finally to the world of venture capital. His perspective on investment focus on dual-use technologies, which are applicable in both commercial and government sectors, is shaped by his unique experiences and his belief in their transformative potential. Jensen, who now heads Harpoon Ventures, sees these technologies as having significant geopolitical implications in today's world. He invests in next-generation technologies like AI, cybersecurity, and deep tech, with the vision of these innovations transforming businesses and enhancing national security and defense capabilities. His investment approach reflects his conviction in the United States maintaining its technological edge to continue being a global symbol of hope and democracy.

ShakeDown Radio - February 2024 - Episode 702 - EDM Music Podcast Website: https://www.podomatic.com/podcasts/chris-carragher1977 Mixcloud: http://www.mixcloud.com/chriscaggs Amazon Music Podcasts: https://bit.ly/3PhNuvZ Apple Podcasts / iTunes:  https://apple.co/3tfyyDP Google Podcasts: https://bit.ly/42JlfcL iHeart Radio: https://ihr.fm/3ss7wr2 Tune In App: https://bit.ly/3qTGsPF Castbox: https://bit.ly/3maXTcb Follow Chris Caggs on Social Media: Threads @ChrisCaggs Facebook Friend Page www.facebook.com/chriscaggs Facebook Fan Page www.facebook.com/chriscaggsradio X www.twitter.com/chriscaggs Instagram www.instagram.com/chriscaggs TikTok @ChrisCaggs Hashtag #ChrisCaggs #ShakedownRadio  This podcast will be released each week at 8am every Friday Sydney Australia Time With thanks to Global PR Pool, Inflyte App, PLAY MPE & Xelon Entertainment SHAKEDOWN RADIO Chris Caggs now has his very own dedicated Radio Channel for all the Shakedown Music and Latest and reloaded shows. Dance, Edm, Rnb and Hip hop.  Available on the Liquid Radio Network www.liquidradio.au Over the span of 25 Years across 15 Radio Stations - Chris Caggs has been on air at: Groove FM 96.9FM & 94.5FM - Sydney Groove FM 97.3FM - Brisbane DJ-FM 87.6FM - Sydney 2RDJ 88.1FM - Sydney 2NSB 99.3FM - Northside Radio Sydney Pump FM 99.3FM - Sydney 2ICR Radio - Sydney Mix It Up Radio - Brisbane STR8OUT Radio - Melbourne Mixxbosses Radio - Sydney Urban Movement Radio - Brisbane Liquid Radio - Snowy Mountains New South Wales - Dance Starter FM - Sydney - Dance Tune 1 Radio - Perth - Dance 4PLAY Radio - Queensland - Dance V1Radio - Melbourne - Dance Tracklist 1. Dannii Minogue & Autone - Thinking 'Bout Us 2. Disclosure - You & Me (Rivo Remix) (Radio Edit) 3. Gotye feat Kimba, FISHER, Chris Lake, Sante Sansone - Somebody (2924) 4. Jax Jones & Zoe Wees - Never Be Lonely (Radio Edit) 5. Jazzy - Shooting Star (Other) 6. Martial Simon & Narissa - 10 to 5 (Radio Edit) 7. Sophie Ellis-Bexter - Murder On The Dancefloor (PNAU Remix) (Radio Edit) 8. Super Disco Club - Do You Want My Love 9. BUNT - Clouds (Tiesto Extended Remix) 10. Deeper Purpose & Guz feat Dope Earth Alien - That Sound (Extended Mix) 11. Harpoon, Needs No Sleep, TAE - So Dangerous (Extended Mix) 12. Pink Panda, Benny Benassi & Alle Farben feat Dave Warren - Set You Free (Extended Mix) 13. Steve Angello - Me (Extended Mix) 14. Afrojack, Timmy Trumpet & Lil Jon - We Can't Stop 15. David Guetta & Mason vs Princess Superstar - Perfect (Exceeder)

ShakeDown Radio - February 2024 - Episode 702 - EDM Music Podcast Website: https://www.podomatic.com/podcasts/chris-carragher1977 Mixcloud: http://www.mixcloud.com/chriscaggs Amazon Music Podcasts: https://bit.ly/3PhNuvZ Apple Podcasts / iTunes:  https://apple.co/3tfyyDP Google Podcasts: https://bit.ly/42JlfcL iHeart Radio: https://ihr.fm/3ss7wr2 Tune In App: https://bit.ly/3qTGsPF Castbox: https://bit.ly/3maXTcb Follow Chris Caggs on Social Media: Threads @ChrisCaggs Facebook Friend Page www.facebook.com/chriscaggs Facebook Fan Page www.facebook.com/chriscaggsradio X www.twitter.com/chriscaggs Instagram www.instagram.com/chriscaggs TikTok @ChrisCaggs Hashtag #ChrisCaggs #ShakedownRadio  This podcast will be released each week at 8am every Friday Sydney Australia Time With thanks to Global PR Pool, Inflyte App, PLAY MPE & Xelon Entertainment SHAKEDOWN RADIO Chris Caggs now has his very own dedicated Radio Channel for all the Shakedown Music and Latest and reloaded shows. Dance, Edm, Rnb and Hip hop.  Available on the Liquid Radio Network www.liquidradio.au Over the span of 25 Years across 15 Radio Stations - Chris Caggs has been on air at: Groove FM 96.9FM & 94.5FM - Sydney Groove FM 97.3FM - Brisbane DJ-FM 87.6FM - Sydney 2RDJ 88.1FM - Sydney 2NSB 99.3FM - Northside Radio Sydney Pump FM 99.3FM - Sydney 2ICR Radio - Sydney Mix It Up Radio - Brisbane STR8OUT Radio - Melbourne Mixxbosses Radio - Sydney Urban Movement Radio - Brisbane Liquid Radio - Snowy Mountains New South Wales - Dance Starter FM - Sydney - Dance Tune 1 Radio - Perth - Dance 4PLAY Radio - Queensland - Dance V1Radio - Melbourne - Dance Tracklist 1. Dannii Minogue & Autone - Thinking 'Bout Us 2. Disclosure - You & Me (Rivo Remix) (Radio Edit) 3. Gotye feat Kimba, FISHER, Chris Lake, Sante Sansone - Somebody (2924) 4. Jax Jones & Zoe Wees - Never Be Lonely (Radio Edit) 5. Jazzy - Shooting Star (Other) 6. Martial Simon & Narissa - 10 to 5 (Radio Edit) 7. Sophie Ellis-Bexter - Murder On The Dancefloor (PNAU Remix) (Radio Edit) 8. Super Disco Club - Do You Want My Love 9. BUNT - Clouds (Tiesto Extended Remix) 10. Deeper Purpose & Guz feat Dope Earth Alien - That Sound (Extended Mix) 11. Harpoon, Needs No Sleep, TAE - So Dangerous (Extended Mix) 12. Pink Panda, Benny Benassi & Alle Farben feat Dave Warren - Set You Free (Extended Mix) 13. Steve Angello - Me (Extended Mix) 14. Afrojack, Timmy Trumpet & Lil Jon - We Can't Stop 15. David Guetta & Mason vs Princess Superstar - Perfect (Exceeder)

ShakeDown Radio - February 2024 - Episode 702 - EDM Music Podcast Website: https://www.podomatic.com/podcasts/chris-carragher1977 Mixcloud: http://www.mixcloud.com/chriscaggs Amazon Music Podcasts: https://bit.ly/3PhNuvZ Apple Podcasts / iTunes:  https://apple.co/3tfyyDP Google Podcasts: https://bit.ly/42JlfcL iHeart Radio: https://ihr.fm/3ss7wr2 Tune In App: https://bit.ly/3qTGsPF Castbox: https://bit.ly/3maXTcb Follow Chris Caggs on Social Media: Threads @ChrisCaggs Facebook Friend Page www.facebook.com/chriscaggs Facebook Fan Page www.facebook.com/chriscaggsradio X www.twitter.com/chriscaggs Instagram www.instagram.com/chriscaggs TikTok @ChrisCaggs Hashtag #ChrisCaggs #ShakedownRadio  This podcast will be released each week at 8am every Friday Sydney Australia Time With thanks to Global PR Pool, Inflyte App, PLAY MPE & Xelon Entertainment SHAKEDOWN RADIO Chris Caggs now has his very own dedicated Radio Channel for all the Shakedown Music and Latest and reloaded shows. Dance, Edm, Rnb and Hip hop.  Available on the Liquid Radio Network www.liquidradio.au Over the span of 25 Years across 15 Radio Stations - Chris Caggs has been on air at: Groove FM 96.9FM & 94.5FM - Sydney Groove FM 97.3FM - Brisbane DJ-FM 87.6FM - Sydney 2RDJ 88.1FM - Sydney 2NSB 99.3FM - Northside Radio Sydney Pump FM 99.3FM - Sydney 2ICR Radio - Sydney Mix It Up Radio - Brisbane STR8OUT Radio - Melbourne Mixxbosses Radio - Sydney Urban Movement Radio - Brisbane Liquid Radio - Snowy Mountains New South Wales - Dance Starter FM - Sydney - Dance Tune 1 Radio - Perth - Dance 4PLAY Radio - Queensland - Dance V1Radio - Melbourne - Dance Tracklist 1. Dannii Minogue & Autone - Thinking 'Bout Us 2. Disclosure - You & Me (Rivo Remix) (Radio Edit) 3. Gotye feat Kimba, FISHER, Chris Lake, Sante Sansone - Somebody (2924) 4. Jax Jones & Zoe Wees - Never Be Lonely (Radio Edit) 5. Jazzy - Shooting Star (Other) 6. Martial Simon & Narissa - 10 to 5 (Radio Edit) 7. Sophie Ellis-Bexter - Murder On The Dancefloor (PNAU Remix) (Radio Edit) 8. Super Disco Club - Do You Want My Love 9. BUNT - Clouds (Tiesto Extended Remix) 10. Deeper Purpose & Guz feat Dope Earth Alien - That Sound (Extended Mix) 11. Harpoon, Needs No Sleep, TAE - So Dangerous (Extended Mix) 12. Pink Panda, Benny Benassi & Alle Farben feat Dave Warren - Set You Free (Extended Mix) 13. Steve Angello - Me (Extended Mix) 14. Afrojack, Timmy Trumpet & Lil Jon - We Can't Stop 15. David Guetta & Mason vs Princess Superstar - Perfect (Exceeder)

ShakeDown Radio - February 2024 - Episode 702 - EDM MusicPodcast Website:https://www.podomatic.com/podcasts/chris-carragher1977Mixcloud: http://www.mixcloud.com/chriscaggsAmazon Music Podcasts: https://bit.ly/3PhNuvZApple Podcasts / iTunes:  https://apple.co/3tfyyDPGoogle Podcasts: https://bit.ly/42JlfcLiHeart Radio: https://ihr.fm/3ss7wr2Tune In App: https://bit.ly/3qTGsPFCastbox: https://bit.ly/3maXTcbFollow Chris Caggs on Social Media:Threads @ChrisCaggsFacebook Friend Page www.facebook.com/chriscaggsFacebook Fan Page www.facebook.com/chriscaggsradioX www.twitter.com/chriscaggsInstagram www.instagram.com/chriscaggsTikTok @ChrisCaggsHashtag #ChrisCaggs #ShakedownRadio With thanks to Global PR Pool, Inflyte App, PLAY MPE & Xelon EntertainmentOver the span of 25 Years across 15 Radio Stations - Chris Caggs has been on air at:Groove FM 96.9FM & 94.5FM - SydneyGroove FM 97.3FM - BrisbaneDJ-FM 87.6FM - Sydney2RDJ 88.1FM - Sydney2NSB 99.3FM - Northside Radio SydneyPump FM 99.3FM - Sydney2ICR Radio - SydneyMix It Up Radio - BrisbaneSTR8OUT Radio - MelbourneMixxbosses Radio - SydneyUrban Movement Radio - BrisbaneLiquid Radio - Snowy Mountains New South Wales - DanceStarter FM - Sydney - DanceTune 1 Radio - Perth - Dance4PLAY Radio - Queensland - DanceV1Radio - Melbourne - DanceTracklist1. Dannii Minogue & Autone - Thinking 'Bout Us2. Disclosure - You & Me (Rivo Remix) (Radio Edit)3. Gotye feat Kimba, FISHER, Chris Lake, Sante Sansone - Somebody (2924)4. Jax Jones & Zoe Wees - Never Be Lonely (Radio Edit)5. Jazzy - Shooting Star (Other)6. Martial Simon & Narissa - 10 to 5 (Radio Edit)7. Sophie Ellis-Bexter - Murder On The Dancefloor (PNAU Remix) (Radio Edit)8. Super Disco Club - Do You Want My Love9. BUNT - Clouds (Tiesto Extended Remix)10. Deeper Purpose & Guz feat Dope Earth Alien - That Sound (Extended Mix)11. Harpoon, Needs No Sleep, TAE - So Dangerous (Extended Mix)12. Pink Panda, Benny Benassi & Alle Farben feat Dave Warren - Set You Free (Extended Mix)13. Steve Angello - Me (Extended Mix)14. Afrojack, Timmy Trumpet & Lil Jon - We Can't Stop15. David Guetta & Mason vs Princess Superstar - Perfect (Exceeder)

ShakeDown Radio - February 2024 - Episode 702 - EDM MusicPodcast Website:https://www.podomatic.com/podcasts/chris-carragher1977Mixcloud: http://www.mixcloud.com/chriscaggsAmazon Music Podcasts: https://bit.ly/3PhNuvZApple Podcasts / iTunes:  https://apple.co/3tfyyDPGoogle Podcasts: https://bit.ly/42JlfcLiHeart Radio: https://ihr.fm/3ss7wr2Tune In App: https://bit.ly/3qTGsPFCastbox: https://bit.ly/3maXTcbFollow Chris Caggs on Social Media:Threads @ChrisCaggsFacebook Friend Page www.facebook.com/chriscaggsFacebook Fan Page www.facebook.com/chriscaggsradioX www.twitter.com/chriscaggsInstagram www.instagram.com/chriscaggsTikTok @ChrisCaggsHashtag #ChrisCaggs #ShakedownRadio With thanks to Global PR Pool, Inflyte App, PLAY MPE & Xelon EntertainmentOver the span of 25 Years across 15 Radio Stations - Chris Caggs has been on air at:Groove FM 96.9FM & 94.5FM - SydneyGroove FM 97.3FM - BrisbaneDJ-FM 87.6FM - Sydney2RDJ 88.1FM - Sydney2NSB 99.3FM - Northside Radio SydneyPump FM 99.3FM - Sydney2ICR Radio - SydneyMix It Up Radio - BrisbaneSTR8OUT Radio - MelbourneMixxbosses Radio - SydneyUrban Movement Radio - BrisbaneLiquid Radio - Snowy Mountains New South Wales - DanceStarter FM - Sydney - DanceTune 1 Radio - Perth - Dance4PLAY Radio - Queensland - DanceV1Radio - Melbourne - DanceTracklist1. Dannii Minogue & Autone - Thinking 'Bout Us2. Disclosure - You & Me (Rivo Remix) (Radio Edit)3. Gotye feat Kimba, FISHER, Chris Lake, Sante Sansone - Somebody (2924)4. Jax Jones & Zoe Wees - Never Be Lonely (Radio Edit)5. Jazzy - Shooting Star (Other)6. Martial Simon & Narissa - 10 to 5 (Radio Edit)7. Sophie Ellis-Bexter - Murder On The Dancefloor (PNAU Remix) (Radio Edit)8. Super Disco Club - Do You Want My Love9. BUNT - Clouds (Tiesto Extended Remix)10. Deeper Purpose & Guz feat Dope Earth Alien - That Sound (Extended Mix)11. Harpoon, Needs No Sleep, TAE - So Dangerous (Extended Mix)12. Pink Panda, Benny Benassi & Alle Farben feat Dave Warren - Set You Free (Extended Mix)13. Steve Angello - Me (Extended Mix)14. Afrojack, Timmy Trumpet & Lil Jon - We Can't Stop15. David Guetta & Mason vs Princess Superstar - Perfect (Exceeder)

ShakeDown Radio - February 2024 - Episode 702 - EDM Music Podcast Website: https://www.podomatic.com/podcasts/chris-carragher1977 Mixcloud: http://www.mixcloud.com/chriscaggs Amazon Music Podcasts: https://bit.ly/3PhNuvZ Apple Podcasts / iTunes:  https://apple.co/3tfyyDP Google Podcasts: https://bit.ly/42JlfcL iHeart Radio: https://ihr.fm/3ss7wr2 Tune In App: https://bit.ly/3qTGsPF Castbox: https://bit.ly/3maXTcb Follow Chris Caggs on Social Media: Threads @ChrisCaggs Facebook Friend Page www.facebook.com/chriscaggs Facebook Fan Page www.facebook.com/chriscaggsradio X www.twitter.com/chriscaggs Instagram www.instagram.com/chriscaggs TikTok @ChrisCaggs Hashtag #ChrisCaggs #ShakedownRadio  This podcast will be released each week at 8am every Friday Sydney Australia Time With thanks to Global PR Pool, Inflyte App, PLAY MPE & Xelon Entertainment SHAKEDOWN RADIO Chris Caggs now has his very own dedicated Radio Channel for all the Shakedown Music and Latest and reloaded shows.Dance, Edm, Rnb and Hip hop. Available on the Liquid Radio Network www.liquidradio.au Over the span of 25 Years across 15 Radio Stations - Chris Caggs has been on air at: Groove FM 96.9FM & 94.5FM - Sydney Groove FM 97.3FM - Brisbane DJ-FM 87.6FM - Sydney 2RDJ 88.1FM - Sydney 2NSB 99.3FM - Northside Radio Sydney Pump FM 99.3FM - Sydney 2ICR Radio - Sydney Mix It Up Radio - Brisbane STR8OUT Radio - Melbourne Mixxbosses Radio - Sydney Urban Movement Radio - Brisbane Liquid Radio - Snowy Mountains New South Wales - Dance Starter FM - Sydney - Dance Tune 1 Radio - Perth - Dance 4PLAY Radio - Queensland - Dance V1Radio - Melbourne - Dance Tracklist 1. Dannii Minogue & Autone - Thinking 'Bout Us 2. Disclosure - You & Me (Rivo Remix) (Radio Edit) 3. Gotye feat Kimba, FISHER, Chris Lake, Sante Sansone - Somebody (2924) 4. Jax Jones & Zoe Wees - Never Be Lonely (Radio Edit) 5. Jazzy - Shooting Star (Other) 6. Martial Simon & Narissa - 10 to 5 (Radio Edit) 7. Sophie Ellis-Bexter - Murder On The Dancefloor (PNAU Remix) (Radio Edit) 8. Super Disco Club - Do You Want My Love 9. BUNT - Clouds (Tiesto Extended Remix) 10. Deeper Purpose & Guz feat Dope Earth Alien - That Sound (Extended Mix) 11. Harpoon, Needs No Sleep, TAE - So Dangerous (Extended Mix) 12. Pink Panda, Benny Benassi & Alle Farben feat Dave Warren - Set You Free (Extended Mix) 13. Steve Angello - Me (Extended Mix) 14. Afrojack, Timmy Trumpet & Lil Jon - We Can't Stop 15. David Guetta & Mason vs Princess Superstar - Perfect (Exceeder)

We get some more details on the festivities surrounding Udonis Haslem's big night We determine which team is most likely to experience an upset this playoff weekend Derrick Henry had some things to say like... he wanted to play for the Miami Dolphins?  This has Tobin dusting off his Harpoon as he tests the water on a potential acquisition Leroy bursts his bubble with reality With a big weekend ahead of us, we find out what games "Tickle Leroy's Fancyyyyyy!"

Cautious optimism was the theme during a J.P. Morgan Healthcare Conference week that featured patchy skies, large-but-not-mega deals and a surfeit of sideline summits around San Francisco's Union Square. BioCentury's editorial team discusses the week's M&A deals, including J&J's $2 billion takeout of ADC company Ambrx, and Merck & Co. acquiring T cell engager biotech Harpoon for nearly $700 million; takeaways from the Sachs Neuroscience Innovation Forum and other adjacent forums; and investor sentiment heading into the New Year.

Chris Grier brings in a pro bowler with his always sharp Harpoon! If the Dolphins beat the Chiefs how should the Fan Base feel How Much does Bam love playing next to Nikola Jovic Leroy is exhausted by the flip floppery Jimmy Butler speaks to the media and assures us he should return soon We get a Marcos mixed bag! Christian Wilkins is Tough as nails Mac Jones future in New England Jimmy Kimmel and Aaron Rodgers beef heats up Mike McDaniel on people will  focus on why we cant, I'm focused on why we can!

A blind boy lives in Greenland with his parents and his aunt. The aunt is always complaining, so the boy's mother sends her away, but one night, there is a storm and the boy hears his aunt being struck by lightning. The aunt goes mad, and only the blind boy can save her, but he'll have to travel far from home to do so... Go to EasyStoriesInEnglish.com/Tusk for the full transcript. Mit dem Code easystories erhältst du das 12-Monatsabo von Babbel zum Preis von nur 6 Monaten. Das Angebot gilt bis zum 31. Dezember 2023. Einfach auf babbel.com/audio einlösen und loslegen. Get episodes without adverts + bonus episodes at EasyStoriesInEnglish.com/Support. Your support is appreciated! Level: Intermediate. Genre: Children's. Vocabulary: Narwhal, Tusk, Keen (ear), Raven, Grumble, Exile, Yank, Bolt of lightning, Migrate (illness), Rot, Flesh, Whittle, Harpoon, Igloo. Setting: Greenland. Word Count: 2831. Author: Howard Norman. Learn more about your ad choices. Visit megaphone.fm/adchoices

Featured Guests: Larsen Jensen, founder & general partner, Harpoon Ventures | Andy Harrison, CEO & general partner, Section 32 | Kenny Tomlin, co-founder, Court Avenue Harpoon Ventures, a firm led by a former Olympian and Navy Seal, raises $125 million, the SEC is skeptical of the use and supervision of AI by investment advisers, and an expert marketer joins the show to predict trends in 2024. Watch Demo Day's first VIDEO: https://www.youtube.com/watch?v=r4VAjjkEBw4 Read our newsletter: https://venture-daily.beehiiv.com/subscribe

Bloomberg has reported that the US has struck a deal to sell 400 ground-based Harpoon missiles to Taiwan, which will increase tensions with China. It looks as if, as the Ukraine war is lost, the Biden Administration - backed by Republicans - are looking for a "new" Ukraine. Also today: Peace is breaking out in the Middle East as the US is looking more and more irrelevant. Finally: Germany shoots itself in the head. Again. Get your tickets to the Ron Paul Institute's June 3rd Houston Conference: https://www.eventbrite.com/e/they-lie-nihilism-and-the-war-on-truth-tickets-590534212727 Show Sponsor Just go to https://4Patriots.com and use code RON to get 10% off your first purchase of 4Patriots Survival Food. That's https://4Patriots.com, use code RON. Show Sponsor: American Financing - tell them Ron Paul Liberty Report sent you: https://www.americanfinancing.net/ron (Disclaimer: NMLS 182334 nmlwconsumeraccess.org)